Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 601 - 625 of 11800 in total
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Description: … (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. …
Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the...
Approved
Investigational
Matched Description: … It is a more commonly prescribed drug in Europe. ... It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional ... In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical …
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is...
Approved
Matched Description: … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever …
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Description: … compared to 16.2 months for patients taking a placebo [L1295]. ... Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding ... In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant …
Approved
Experimental
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Description: … [A189327] Avapritinib shares a similar mechanism with [ripretinib]. ... Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide ... [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions ... neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 ... Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial ... [A261276] It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. …
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild,...
Approved
Vet approved
Withdrawn
Matched Description: … Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive …
Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.
Approved
Matched Description: … in people with a history of penicillin allergy. ... Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies ... The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for …
A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Approved
Investigational
Matched Description: … It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator ... , and also a centrally acting neurotransmitter. ... A depressor amine derived by enzymatic decarboxylation of histidine. …
Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition but is more commonly used in veterinary medicine. Radiolabelled compound, DB09293, is used as a diagnostic tool to evaluate thyroid function...
Approved
Matched Description: … Sodium iodide is a water-soluble ionic compound with a crystal lattice. ... Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition ... Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology …
Approved
Investigational
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … significantly debilitating with a profound impact on the quality of life. ... Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. …
Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Approved
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... [L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare ... "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … risk for poor outcomes and creating a significant clinical challenge [A31818]. ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and …
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia …
Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Approved
Investigational
Matched Description: … Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent …
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially …
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Description: … An ergot derivative that is a congener of lysergic acid diethylamide. …
Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Approved
Matched Description: … Isometheptene is a sympathomimetic drug that causes vasoconstriction. …
Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational
Matched Description: … Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in ... Medical thrombin is a protein substance produced through a conversion reaction in which prothrombin of ... thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Approved
Matched Description: … A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Displaying drugs 601 - 625 of 11800 in total